Floatz logo

Recombinant Fowlpox-Gm-Csf

Salivary Gland Carcinoma

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Salivary Gland Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
VM Oncology, LLC
Phase 2B
Anti-Her2 Antibody-Drug Conjugate A166
Klus Pharma Inc.
Phase 1/2CCC
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)-
VM Oncology, LLC
Phase 1/2CCC
Lenalidomide
National Cancer Institute (NCI)
Phase 1CC
Sargramostim
National Cancer Institute (NCI)
Phase 1CC

View all 13 →

Same molecule, other indications

Recombinant Fowlpox-Gm-Csf is also rated in:

prostate neoplasmDormant
CCC
Indicative · Phase 1/2
55 / 100
View asset →
salivary gland cancerDormant
CC
Indicative · Phase 1
47 / 100
View asset →
gallbladder adenocarcinomaDormant
CC
Indicative · Phase 1
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →